Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $4.1 million.

  • Biodesix's Other Operating Expenses fell 157.93% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year increase of 1102.0%. This contributed to the annual value of $15.8 million for FY2024, which is 2112.0% up from last year.
  • Per Biodesix's latest filing, its Other Operating Expenses stood at $4.1 million for Q3 2025, which was down 157.93% from $4.1 million recorded in Q2 2025.
  • Biodesix's Other Operating Expenses' 5-year high stood at $19.2 million during Q1 2021, with a 5-year trough of $2.5 million in Q4 2021.
  • For the 5-year period, Biodesix's Other Operating Expenses averaged around $4.6 million, with its median value being $3.6 million (2022).
  • Data for Biodesix's Other Operating Expenses shows a peak YoY increase of 74231.19% (in 2021) and a maximum YoY decrease of 8282.23% (in 2021) over the last 5 years.
  • Over the past 5 years, Biodesix's Other Operating Expenses (Quarter) stood at $2.5 million in 2021, then surged by 32.61% to $3.3 million in 2022, then grew by 2.78% to $3.4 million in 2023, then soared by 30.81% to $4.4 million in 2024, then dropped by 7.47% to $4.1 million in 2025.
  • Its last three reported values are $4.1 million in Q3 2025, $4.1 million for Q2 2025, and $3.8 million during Q1 2025.